Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Description

This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.

Conditions

Specific Advanced Solid Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.

ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects With Advanced Solid Tumors

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Condition
Specific Advanced Solid Tumors
Intervention / Treatment

-

Contacts and Locations

Huntersville

Carolina BioOncology Institute, Huntersville, North Carolina, United States, 28078

Houston

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77054

San Antonio

NEXT Oncology, San Antonio, Texas, United States, 78229

Fairfax

Next Virginia, Fairfax, Virginia, United States, 22031

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Signed written informed consent.
  • 2. Histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors.
  • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months.
  • 4. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST v1.1.
  • 5. Adequate organ functions.
  • 6. Must have progressed after prior line of treatment.
  • 1. Participants with known symptomatic brain metastases.
  • 2. Participant had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug.
  • 3. Women who are pregnant or lactating.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Acrivon Therapeutics,

Study Record Dates

2026-12-12